Employers should prepare for a major increase in healthcare costs in 2025, with new projections showing rises of 8-9 percent or more over this year’s spending.
This dramatic uptick comes as a result of several key factors putting pressure on health plans, including widespread inflation, demand for expensive specialty medications, and a growth in catastrophic claims. Employers that take action now with aggressive cost-cutting strategies may be able to blunt the impact.
Driving Forces Behind the Increase
A number of dynamics are converging to push healthcare costs significantly higher for employers next year. Overall inflation is feeding into rising wages and higher employment, which translates into more expensive health premiums. At the same time, more expensive specialty drugs and services are coming onto the market, leading to an increase in utilization.
According to projections from professional services firm Aon, healthcare costs per employee are estimated to rise by approximately 9% in 2025, reaching over $16,000. This outpaces the 6.4% increase seen from 2023 to 2024, when per-employee costs averaged $14,823. Of that total spend, employers covered $11,956 per worker compared to $2,867 paid by employees.
Another forecast from the International Foundation of Employee Benefit Plans (IFEBP) was slightly more conservative but still showed a steep climb. Their survey of employers revealed expectations for a median increase of 8% in 2025 health plan expenses. This continues an upward trend from 7% jumps anticipated in both 2022 and 2023.
The Role of Specialty Drugs
A major culprit behind escalating health expenses is the surging cost of specialty medications, particularly GLP-1 drugs like Ozempic and Wegovy. While these treatments show promise for weight loss and diabetes, their high monthly price tag of $1,000-$1,500 per prescription quickly adds up. According to experts, demand for GLP-1 drugs is skyrocketing across employer plans.
The introduction of new medications in this class will likely pile on more costs as well. Aon estimates that specialty drugs will account for a full 1% of next year’s 9% rise in total health spend. They require intense oversight, even though specialty treatments make up a small portion of utilization.
In IFEBP’s poll, 20% of employers singled out costly prescription options as the top driver pushing up program expenses. That figure increased from just 16% last year, unseating medical provider costs as the number one factor. Of those citing specialty therapies, 75% pointed to GLP-1 medications in particular.
Catastrophic Claims and Chronic Conditions
While specialty drugs may capture headlines for their shocking price tags, they aren’t the only reason for mounting health expenses. Chronic conditions among employees also take a toll through increased utilization of regular doctor visits, procedures, hospital stays, and medications needed to manage them.
In fact, 20% of organizations surveyed by IFEBP named catastrophic claims as the primary reason costs continue to rise each year, while 16% cited chronic health conditions. Less healthy worker populations end up driving more services, especially complicated treatments for complex long-term diseases.
Even a small number of catastrophic claims can also blow budgets. Just one or two patients with major health emergencies requiring extensive hospitalization and rehab can devastate even the best-funded plan.
Cost Management Strategies
While the projected 8-9% jumps are daunting — with some markets predicting even higher numbers — concentrated efforts around managing utilization and sharing expenses can potentially tame increases. When asked which cost-saving initiatives would have the most impact next year, employers pointed to the following measures.
Utilization control landed on top, with 27% stating that requiring prior authorizations, using nurse advice lines, and instituting disease management protocols would make the biggest difference. These moves ensure treatments and prescriptions are truly medically necessary before being approved.
Shifting more costs to the wallets of employees is also an increasingly important lever cited by 21% of those surveyed. This can include tactics like raising plan deductibles and co-insurance rates across the board or specifically for costly specialty drugs.
Other organizations may tighten dependent eligibility criteria or institute spousal surcharges. While tough to execute, directing more expenses to employees ultimately lightens the load on the company. Moving to stricter formularies that limit expensive brands or exclude certain drug classes altogether is another avenue.
For more Employee Benefits resources, contact INSURICA today.
Copyright © 2024 Smarts Publishing. This is not intended to be exhaustive nor should any discussion or opinions be construed as legal advice. Readers should contact legal counsel or an insurance professional for appropriate advice.
About the Author
Share This Story
Related Blogs
OSHA Announces Top 10 Violations for 2024
OSHA recently revealed its top 10 most frequently cited standards in the 2024 fiscal year using preliminary data. This information is valuable for businesses of all kinds, as it helps them identify common exposures that affect their workforce and gives them the information they need to plan their compliance programs.
Holiday Shopping Online? Remember These Cybersecurity Tips
Online shopping has made it easier than ever to peruse the wares of various businesses and vendors from the comfort of your own home as you search for the perfect gifts this holiday season. However, conducting transactions over the internet always involves inherent risks, as cybercriminals may be lying in wait.
Most Common Vehicle and Driver Violations Leading to Out-of-Service Orders in 2024 Fiscal Year
To help drivers of commercial motor vehicles (CMVs) remain safe and keep trucking businesses in compliance with the Federal Motor Carrier Safety Regulations and Hazardous Materials Regulations, the Federal Motor Carrier Safety Administration records the number of violations discovered through roadside inspections conducted by Motor Carrier Safety Assistance Program inspectors.